Hypogammaglobulinemia acquired secondary to hematological malignancies

Recommended Indications in which IG can be used

Includes but is not limited to:

• chronic lymphocytic leukemia
• lymphoma
• myeloma
• post-hematopoietic stem cell transplant (HSCT)
• recipients of chimeric antigen receptor T-cells (CAR-T)

Order Number: I2-SID

See separate entry for secondary hypogammaglobulinemia in the Immunology Indications section for recommendations, dose and frequency of administration.